The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive insulin products and forced patients to pay more.
F.T.C. Accuses Drug Middlemen of Inflating Insulin Prices
Written by
in
CIGNA Corporation, CVS Caremark Corporation, Drugs (Pharmaceuticals), Drugstores, Express Scripts Inc, Federal Trade Commission, Health Insurance and Managed Care, Insulin, Khan, Lina, Presidential Election of 2024, Prices (Fares, Fees and Rates), Regulation and Deregulation of Industry, Suits and Litigation (Civil)